UroGen Pharma Ltd. (NASDAQ:URGN) Stock Position Increased by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company lifted its holdings in UroGen Pharma Ltd. (NASDAQ:URGN) by 178.1% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 37,486 shares of the company’s stock after purchasing an additional 24,006 shares during the quarter. The Manufacturers Life Insurance Company owned 0.16% of UroGen Pharma worth $399,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently modified their holdings of URGN. JPMorgan Chase & Co. lifted its position in UroGen Pharma by 263.1% in the third quarter. JPMorgan Chase & Co. now owns 68,062 shares of the company’s stock worth $864,000 after purchasing an additional 49,318 shares during the period. Renaissance Technologies LLC bought a new stake in shares of UroGen Pharma in the 4th quarter worth $1,472,000. Bank of New York Mellon Corp lifted its holdings in shares of UroGen Pharma by 7.3% in the fourth quarter. Bank of New York Mellon Corp now owns 93,997 shares of the company’s stock valued at $1,001,000 after buying an additional 6,430 shares during the period. Oppenheimer & Co. Inc. acquired a new stake in shares of UroGen Pharma in the fourth quarter valued at $126,000. Finally, Rhumbline Advisers boosted its stake in UroGen Pharma by 2.8% during the fourth quarter. Rhumbline Advisers now owns 51,270 shares of the company’s stock valued at $546,000 after buying an additional 1,402 shares in the last quarter. Institutional investors own 91.29% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have commented on URGN. D. Boral Capital reiterated a “buy” rating and issued a $25.00 price target on shares of UroGen Pharma in a research report on Thursday, May 8th. Scotiabank initiated coverage on shares of UroGen Pharma in a research note on Wednesday, April 16th. They issued a “sector outperform” rating and a $23.00 price objective on the stock. LADENBURG THALM/SH SH started coverage on shares of UroGen Pharma in a research note on Wednesday, February 19th. They set a “buy” rating and a $31.00 target price for the company. Guggenheim restated a “buy” rating on shares of UroGen Pharma in a report on Tuesday, April 29th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $55.00 price target on shares of UroGen Pharma in a report on Tuesday, May 13th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $32.86.

UroGen Pharma Stock Performance

UroGen Pharma stock opened at $7.31 on Friday. UroGen Pharma Ltd. has a fifty-two week low of $6.46 and a fifty-two week high of $20.70. The firm’s 50 day simple moving average is $10.59 and its 200-day simple moving average is $10.89. The company has a debt-to-equity ratio of 4.77, a current ratio of 9.00 and a quick ratio of 8.77. The company has a market cap of $337.04 million, a P/E ratio of -2.32 and a beta of 0.66.

UroGen Pharma (NASDAQ:URGN) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.92) EPS for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.09). The company had revenue of $20.25 million for the quarter, compared to analysts’ expectations of $22.71 million. As a group, equities research analysts predict that UroGen Pharma Ltd. will post -3.12 EPS for the current year.

UroGen Pharma Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.